Adaptive Biotechnologies struck two non-exclusive agreements with Pfizer to apply Adaptive’s T-cell receptor (TCR) discovery platform to rheumatoid arthritis R&D and to license TCR-antigen mapping data for AI training across multiple disease areas. Adaptive will analyze Pfizer clinical samples to identify enriched disease-associated TCRs and expects upfront payments plus potential milestones that together could approach $890 million on the discovery/licensing side. CEO Chad Robins emphasized the value of Adaptive’s immune-receptor data to speed target discovery and to train machine-learning models for translational programs.